2 Reasons to Watch PFE and 1 to Stay Cautious

Even during a down period for the markets, Pfizer has gone against the grain, climbing to $28.30. Its shares have yielded a 7.1% return over the last six months, beating the S&P 500 by 9.4%. This run-up might have investors contemplating their next move.